Zogenix Provides Corporate Update and Reports Second Quarter 2017 Financial Results

Published: Aug 09, 2017

EMERYVILLE, Calif., Aug. 08, 2017 (GLOBE NEWSWIRE) -- Zogenix, Inc. (NASDAQ:ZGNX), a pharmaceutical company developing therapies for the treatment of orphan and central nervous system (CNS) disorders, today provided a corporate update and announced financial results for the second quarter and six months ended June 30, 2017.

“We remain on target to announce Study 1 top-line results from our ZX008 Phase 3 program in Dravet syndrome late in the third quarter of this year,” said Stephen J. Farr, Ph.D., President and CEO of Zogenix.

Back to news